Atul Q1 FY27 Results (NSE: ATUL)
Signal: Margin expansion
The read
This is a standout quarter — revenue growth accelerated to +25% YoY (from +15% in Q4FY26) and EBITDA margin expanded 700bps YoY to 18.7%, marking the 6th consecutive quarter of YoY margin expansion. The tailwind is a combination of substantial input cost relief (RM % of revenue dropped 1300bps) and genuine operating leverage as employee costs + other expenses grew well below revenue. Performance & Other Chemicals led the charge (revenue +34% YoY), while Life Science Chemicals showed steady but slower growth. PAT of ₹245 Cr (+92% YoY) sets a new high. The quality is high — no exceptional items, no tax flips, and cash EPS growth matches PAT growth.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,847.95 Cr | +25.0% | +10.7% |
| EBIT | ₹344.74 Cr | +96.8% | |
| Net profit | ₹245.3 Cr | +91.7% | |
| EPS | ₹83.32 | +92.0% | |
| EBIT margin | 18.7% |
P&L walk
Strong top-line growth (+25% YoY) with exceptional margin expansion — EBITDA margin jumped 700bps YoY to 18.7%, driven by a sharp decline in raw material cost as % of revenue (-1300bps), operating leverage (employee cost + other expenses grew far slower than revenue), and lower depreciation intensity. PAT grew 92% YoY tracking operating profit, with minimal dilution.
Segments
Performance & Other Chemicals is the star — revenue ₹1,427 Cr (+33.8% YoY, +15.0% QoQ) and segment result ₹240 Cr (+139.8% YoY), contributing 71% of segment results. Life Science Chemicals grew modestly (revenue +4.5% YoY, result +35.6% YoY). The consolidated outperformance vs standalone is driven by subsidiary revenues in Performance & Other Chemicals.
Key positives
- Revenue ₹1,848 Cr (+25.0% YoY) — fastest growth in at least 6 quarters.
- EBITDA margin expanded 700bps YoY to 18.7% — 6th consecutive quarter of YoY margin expansion.
- Operating leverage confirmed: EBITDA grew +96.8% vs revenue +25.0% (+72pp gap).
- Performance & Other Chemicals segment revenue +33.8% YoY, segment result +139.8% YoY.
- PAT ₹245 Cr (+91.7% YoY) — all-time quarterly high.
- Virtually debt-free with D/E 0.03; finance cost negligible at ₹4 Cr.
- EPS ₹83.32 (+92.0% YoY) — no dilution.
Key concerns
- Cost of materials consumed jumped QoQ (from 53.2% to 59.7% of revenue) — sequential input cost pressure may have increased in June qtr.
- Life Science Chemicals revenue growth modest (+4.5% YoY) — could indicate pricing or volume headwinds in the API/agrochemical sub-segments.
- Other income halved QoQ (₹33.3 Cr vs ₹89.6 Cr) — a volatile component that can distort earnings trends.
- Standalone PAT declined slightly QoQ (-1.4%) even as consolidated rose, suggesting subsidiary performance drove the beat.
Research and educational content only. Not investment advice.